Compare Amgen, Inc. (AMGN) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Annaly Capital Management, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Annaly Capital Management, Inc. trades at $22.89 (market cap $16.75B). The key difference: Amgen, Inc. is far larger — about 11.7× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.12%). Which is the better fit depends on your goals.
| AMGN | NLY | |
|---|---|---|
Market Cap | $196.12B | $16.75B |
Sector | Health | Financials |
52-Week High | $388.16 | $24.40 |
52-Week Low | $271.18 | $19.47 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 13.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Annaly Capital Management (NLY) trades at $22.86, up 0.57% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 91.17% net income margin and 15.61% ROE, supported by a recent dividend increase to $0.75 per share. Analyst consensus is bullish with a $24.40 price target, reflecting confidence in its mortgage REIT model amid evolving Fed policy.
NLY offers a high-yield opportunity with manageable risks from interest rate sensitivity. The stock's attractive valuation (P/E 7.37, P/B 1.16) and positive cash flow trends support upside potential, though investors must monitor leverage and macroeconomic shifts that impact mortgage spreads and refinancing activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
